OncoTraj: a public benchmark for longitudinal resistance prediction in EGFR-mutant non-small-cell lung cancer on osimertinib
Focuses on OncoTraj: a public benchmark for longitudinal resistance prediction in EGFR-mutant non-small-cell lung cancer on osimertinib.
At a glance
- Source
- arXiv
- Published
- Jun 11, 2026
- Read time
- 1 min read
- Primary lane
- Machine Learning
Quick read
4 bullets- Focuses on OncoTraj: a public benchmark for longitudinal resistance prediction in EGFR-mutant non-small-cell lung cancer on osimertinib.
- Resistance to first-line osimertinib in EGFR-mutant non-small-cell lung cancer (NSCLC) is the canonical example of predictable clonal evolution under therapeutic pressure, yet no public benchmark...
- We introduce OncoTraj, a public benchmark of 813 EGFR-mutant NSCLC patients receiving first-line osimertinib, harmonized from three real-world clinical-genomic sources: MSK-CHORD (672 patients), AACR Project GENIE BPC...
- Clinical and bio workflows punish fragile models quickly. What matters here is whether the method improves trust, robustness, or operational cost enough to make it usable in expensive real settings.
Чому це важливо
Clinical and bio workflows punish fragile models quickly. What matters here is whether the method improves trust, robustness, or operational cost enough to make it usable in expensive real settings.
Builder takeaway
arXiv published this update in the Machine Learning lane. Use the original source for details, then compare it with related briefings before changing a roadmap, workflow, or production system.
Коротко
- Focuses on OncoTraj: a public benchmark for longitudinal resistance prediction in EGFR-mutant non-small-cell lung cancer on osimertinib.
- Resistance to first-line osimertinib in EGFR-mutant non-small-cell lung cancer (NSCLC) is the canonical example of predictable clonal evolution under therapeutic pressure, yet no public benchmark...
- We introduce OncoTraj, a public benchmark of 813 EGFR-mutant NSCLC patients receiving first-line osimertinib, harmonized from three real-world clinical-genomic sources: MSK-CHORD (672 patients), AACR Project GENIE BPC...
Stay ahead with daily AI briefings
Follow the feed, share the briefing, or jump back into the archive.